Healthcare [ 2/11 ] | Biotechnology [ 32/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 14, 22 | -0.31
Decreased by
-34.78%
|
-0.68
Increased by
+54.41%
|
Aug 15, 22 | -0.17
Increased by
+26.09%
|
-0.57
Increased by
+70.18%
|
May 16, 22 | -0.64
Decreased by
-481.82%
|
-0.41
Decreased by
-56.10%
|
Mar 2, 22 | -0.31
Increased by
+38.00%
|
-0.01
Decreased by
-3.00 K%
|
Nov 19, 21 | -0.23
Increased by
+54.90%
|
-0.28
Increased by
+17.86%
|
Aug 10, 21 | -0.23
Increased by
+58.93%
|
-0.36
Increased by
+36.11%
|
May 17, 21 | -0.11
Increased by
+77.55%
|
-0.44
Increased by
+75.00%
|
Mar 1, 21 | -0.50
Increased by
+1.96%
|
-0.41
Decreased by
-21.95%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 0.00
Decreased by
N/A%
|
-5.01 M
Decreased by
-52.98%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
N/A%
|
-2.67 M
Increased by
+17.36%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 0.00
Decreased by
-100.00%
|
-9.18 M
Decreased by
-506.61%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 21 | 360.00 K
Increased by
+N/A%
|
-4.42 M
Increased by
+29.13%
|
Decreased by
-1.23 K%
Decreased by
N/A%
|
Sep 30, 21 | 0.00
Decreased by
N/A%
|
-3.27 M
Increased by
+44.79%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 21 | 0.00
Decreased by
N/A%
|
-3.23 M
Increased by
+44.08%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 21 | 4.00 M
Increased by
+N/A%
|
-1.51 M
Increased by
+69.42%
|
Decreased by
-37.85%
Decreased by
N/A%
|
Dec 31, 20 | 0.00
Decreased by
N/A%
|
-6.24 M
Decreased by
-20.97%
|
Decreased by
N/A%
Decreased by
N/A%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.